{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:52:51Z","timestamp":1792205571641,"version":"4.4.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00203-025-04415-y","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T04:48:46Z","timestamp":1756529326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent advancements in drug development for pulmonary tuberculosis"],"prefix":"10.1007","volume":"207","author":[{"given":"Koushik","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritam","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirat Kumar","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somjyoti","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarnali","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"4415_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00005-018-0511-0","volume":"66","author":"B Abd-Nikfarjam","year":"2018","unstructured":"Abd-Nikfarjam B, Nassiri-Asl M, Hajiaghayi M, Naserpour Farivar T (2018) Role of Chicoric acid and 13-Cis retinoic acid in Mycobacterium tuberculosis infection control by human U937 macrophage. Arch Immunol Ther Exp (Warsz) 66:399\u2013406. https:\/\/doi.org\/10.1007\/s00005-018-0511-0","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"4415_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5588\/ijtld.22.0548","volume":"27","author":"OO Adewole","year":"2023","unstructured":"Adewole OO, Omotoso BA, Ogunsina M et al (2023) Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial. Int J Tuberc Lung Dis 27:226\u2013228. https:\/\/doi.org\/10.5588\/ijtld.22.0548","journal-title":"Int J Tuberc Lung Dis"},{"key":"4415_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000528274","volume":"102","author":"JM Aguilar Diaz","year":"2023","unstructured":"Aguilar Diaz JM, Abulfathi AA, te Brake LH et al (2023) New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians. Respiration 102:83\u2013100. https:\/\/doi.org\/10.1159\/000528274","journal-title":"Respiration"},{"key":"4415_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/s0140-6736(18)31644-1","volume":"392","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ahuja SD, Akkerman OW et al (2018) Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 392:821\u2013834. https:\/\/doi.org\/10.1016\/s0140-6736(18)31644-1","journal-title":"Lancet"},{"key":"4415_CR6","doi-asserted-by":"publisher","unstructured":"Al-Jaberi FAH, Crone CG, Lindenstr\u00f8m T et al (2022) Reduced vitamin D-induced Cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.1038960","DOI":"10.3389\/fimmu.2022.1038960"},{"key":"4415_CR5","doi-asserted-by":"publisher","unstructured":"Alagarsamy S, Kandasamy S, Kandasamy R et al (2024) Polymeric nanoparticles for oral delivery of biopharmaceuticals: an overview. J Innov Appl Pharm Sci JIAPS 1\u20138. https:\/\/doi.org\/10.37022\/jiaps.v9i1.565","DOI":"10.37022\/jiaps.v9i1.565"},{"key":"4415_CR7","doi-asserted-by":"publisher","first-page":"112175","DOI":"10.1016\/j.ejmech.2020.112175","volume":"192","author":"Q An","year":"2020","unstructured":"An Q, Li C, Chen Y et al (2020) Repurposed drug candidates for antituberculosis therapy. Eur J Med Chem 192:112175. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112175","journal-title":"Eur J Med Chem"},{"key":"4415_CR8","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1021\/acsbiomaterials.1c00807","volume":"8","author":"CW Ang","year":"2022","unstructured":"Ang CW, Tan L, Qu Z et al (2022) Mesoporous silica nanoparticles improve oral delivery of antitubercular bicyclic nitroimidazoles. ACS Biomater Sci Eng 8:4196\u20134206. https:\/\/doi.org\/10.1021\/acsbiomaterials.1c00807","journal-title":"ACS Biomater Sci Eng"},{"key":"4415_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.18683\/germs.2020.1188","volume":"10","author":"D Arora","year":"2020","unstructured":"Arora D, Dhanashree B (2020) Utility of smear microscopy and GeneXpert for the detection of Mycobacterium tuberculosis in clinical samples. Germs 10:81\u201387. https:\/\/doi.org\/10.18683\/germs.2020.1188","journal-title":"Germs"},{"key":"4415_CR10","doi-asserted-by":"publisher","first-page":"114588","DOI":"10.1016\/j.biopha.2023.114588","volume":"162","author":"S Ayodele","year":"2023","unstructured":"Ayodele S, Kumar P, van Eyk A, Choonara YE (2023) Advances in Immunomodulatory strategies for host-directed therapies in combating tuberculosis. Biomed Pharmacother 162:114588. https:\/\/doi.org\/10.1016\/j.biopha.2023.114588","journal-title":"Biomed Pharmacother"},{"key":"4415_CR11","volume-title":"Linezolid","author":"A Azzouz","year":"2024","unstructured":"Azzouz A, Preuss CV (2024) Linezolid. In: StatPearls. StatPearls Publishing, Treasure Island"},{"key":"4415_CR12","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi S (2023) WHO\u2019s global tuberculosis report 2022. Lancet Microbe 4:e20. https:\/\/doi.org\/10.1016\/S2666-5247(22)00359-7","journal-title":"Lancet Microbe"},{"key":"4415_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/med.21602","volume":"40","author":"A Bahuguna","year":"2020","unstructured":"Bahuguna A, Rawat DS (2020) An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev 40:263\u2013292. https:\/\/doi.org\/10.1002\/med.21602","journal-title":"Med Res Rev"},{"key":"4415_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2174\/1570159X15666171016163510","volume":"16","author":"MH Baig","year":"2018","unstructured":"Baig MH, Ahmad K, Rabbani G et al (2018) Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders. Curr Neuropharmacol 16:740\u2013748. https:\/\/doi.org\/10.2174\/1570159X15666171016163510","journal-title":"Curr Neuropharmacol"},{"key":"4415_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jmgm.2015.05.012","volume":"60","author":"RG Bellini","year":"2015","unstructured":"Bellini RG, Guimar\u00e3es AP, Pacheco MAC et al (2015) Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer. J Mol Graph Model 60:34\u201342. https:\/\/doi.org\/10.1016\/j.jmgm.2015.05.012","journal-title":"J Mol Graph Model"},{"key":"4415_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2214\/ajr.125.4.842","volume":"125","author":"YM Berkmen","year":"1975","unstructured":"Berkmen YM, Lande A (1975) Chest roentgenography as a window to the diagnosis of takayasu\u2019s arteritis. Am J Roentgenol Radium Ther Nucl Med 125:842\u2013846. https:\/\/doi.org\/10.2214\/ajr.125.4.842","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"4415_CR17","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1039\/D2BM01835G","volume":"11","author":"M Bhandari","year":"2023","unstructured":"Bhandari M, Soria-Carrera H, Wohlmann J et al (2023) Subcellular localization and therapeutic efficacy of polymeric micellar nanoparticles encapsulating bedaquiline for tuberculosis treatment in zebrafish. Biomater Sci 11:2103\u20132114. https:\/\/doi.org\/10.1039\/D2BM01835G","journal-title":"Biomater Sci"},{"key":"4415_CR18","doi-asserted-by":"publisher","first-page":"106809","DOI":"10.1016\/j.intimp.2020.106809","volume":"87","author":"A Bhaskar","year":"2020","unstructured":"Bhaskar A, Kumari A, Singh M et al (2020) [6]-Gingerol exhibits potent anti-mycobacterial and Immunomodulatory activity against tuberculosis. Int Immunopharmacol 87:106809. https:\/\/doi.org\/10.1016\/j.intimp.2020.106809","journal-title":"Int Immunopharmacol"},{"key":"4415_CR19","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1128\/JB.01346-13","volume":"196","author":"F Boldrin","year":"2014","unstructured":"Boldrin F, Ventura M, Degiacomi G et al (2014) The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo. J Bacteriol 196:3441\u20133451. https:\/\/doi.org\/10.1128\/JB.01346-13","journal-title":"J Bacteriol"},{"key":"4415_CR20","doi-asserted-by":"publisher","unstructured":"Cai D, Gao W, Li Z et al (2022) Current development of nano-drug delivery to target macrophages. https:\/\/doi.org\/10.3390\/biomedicines10051203. Biomedicines","DOI":"10.3390\/biomedicines10051203"},{"key":"4415_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3978\/j.issn.2072-1439.2013.11.11","volume":"6","author":"GL Calligaro","year":"2014","unstructured":"Calligaro GL, Moodley L, Symons G, Dheda K (2014) The medical and surgical treatment of drug-resistant tuberculosis. J Thorac Dis 6:186\u2013195. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.11.11","journal-title":"J Thorac Dis"},{"key":"4415_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bioactmat.2024.05.013","volume":"39","author":"CS Carnero Canales","year":"2024","unstructured":"Carnero Canales CS, Marquez Cazorla JI, Marquez Cazorla RM et al (2024) Breaking barriers: the potential of nanosystems in antituberculosis therapy. Bioact Mater 39:106\u2013134. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.05.013","journal-title":"Bioact Mater"},{"key":"4415_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4269\/ajtmh.24-0073","volume":"111","author":"B Castro-Rodr\u00edguez","year":"2024","unstructured":"Castro-Rodr\u00edguez B, Cazar-Ramos C, Franco-Sotomayor G et al (2024) The impact of the Mycobacterium tuberculosis RDRio subfamily on multidrug-resistant tuberculosis in Latin america: a comprehensive review. Am J Trop Med Hyg 111:230\u2013236. https:\/\/doi.org\/10.4269\/ajtmh.24-0073","journal-title":"Am J Trop Med Hyg"},{"key":"4415_CR24","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1039\/D3NA00320E","volume":"5","author":"J Chae","year":"2023","unstructured":"Chae J, Kang SH, Kim J et al (2023) Targeted and efficient delivery of rifampicin to macrophages involved in non-tuberculous mycobacterial infection via mannosylated solid lipid nanoparticles. Nanoscale Adv 5:4536\u20134545. https:\/\/doi.org\/10.1039\/D3NA00320E","journal-title":"Nanoscale Adv"},{"key":"4415_CR25","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","volume":"113","author":"J Chakaya","year":"2021","unstructured":"Chakaya J, Khan M, Ntoumi F et al (2021) Global tuberculosis report 2020\u2014reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis 113:S7\u2013S12. https:\/\/doi.org\/10.1016\/j.ijid.2021.02.107","journal-title":"Int J Infect Dis"},{"key":"4415_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1177\/0885328218814988","volume":"33","author":"G Chen","year":"2019","unstructured":"Chen G, Wu Y, Yu D et al (2019) Isoniazid-loaded chitosan\/carbon nanotubes microspheres promote secondary wound healing of bone tuberculosis. J Biomater Appl 33:989\u2013996. https:\/\/doi.org\/10.1177\/0885328218814988","journal-title":"J Biomater Appl"},{"key":"4415_CR118","doi-asserted-by":"publisher","unstructured":"Chen Y, Liu J, Zhang Q et al (2024) Global burden of MDR-TB and XDR-TB attributable to high fasting plasma glucose from 1990 to 2019: a retrospective analysis based on the global burden of disease study 2019. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. https:\/\/doi.org\/10.1007\/s10096-024-04779-x. 2019","DOI":"10.1007\/s10096-024-04779-x"},{"key":"4415_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/nejmoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N et al (2020) Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 382:893\u2013902. https:\/\/doi.org\/10.1056\/nejmoa1901814","journal-title":"N Engl J Med"},{"key":"4415_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.04.25326549","author":"F Conradie","year":"2025","unstructured":"Conradie F, Badat T, Poswa A et al (2025) BEAT tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis. MedRXiv. https:\/\/doi.org\/10.1101\/2025.05.04.25326549","journal-title":"MedRXiv"},{"key":"4415_CR29","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S1473-3099(22)00222-5","volume":"22","author":"MF Cotton","year":"2022","unstructured":"Cotton MF, Madhi SA, Luabeya AK et al (2022) Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis 22:1472\u20131483. https:\/\/doi.org\/10.1016\/S1473-3099(22)00222-5","journal-title":"Lancet Infect Dis"},{"key":"4415_CR30","volume-title":"Fluoroquinolones for the treatment of respiratory tract infections: a review of clinical effectiveness, cost-effectiveness, and guidelines","author":"T Cowling","year":"2019","unstructured":"Cowling T, Farrah K (2019) Fluoroquinolones for the treatment of respiratory tract infections: a review of clinical effectiveness, cost-effectiveness, and guidelines. Canadian Agency for Drugs and Technologies in Health, Ottawa"},{"key":"4415_CR31","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1164\/rccm.202108-1976OC","volume":"205","author":"V De Jager","year":"2022","unstructured":"De Jager V, Gupte N, Nunes S et al (2022) Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial. Am J Respir Crit Care Med 205:1228\u20131235. https:\/\/doi.org\/10.1164\/rccm.202108-1976OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4415_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/501356","volume":"42","author":"AS De Vriese","year":"2006","unstructured":"De Vriese AS, Van Coster R, Smet J et al (2006) Linezolid-induced Inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111\u20131117. https:\/\/doi.org\/10.1086\/501356","journal-title":"Clin Infect Dis"},{"key":"4415_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM et al (2024) Multidrug-resistant tuberculosis. Nat Rev Dis Primer 10:1\u201327. https:\/\/doi.org\/10.1038\/s41572-024-00504-2","journal-title":"Nat Rev Dis Primer"},{"key":"4415_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijid.2023.04.392","volume":"132","author":"G Diriba","year":"2023","unstructured":"Diriba G, Alemu A, Yenew B et al (2023) Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 132:50\u201363. https:\/\/doi.org\/10.1016\/j.ijid.2023.04.392","journal-title":"Int J Infect Dis"},{"key":"4415_CR35","doi-asserted-by":"publisher","first-page":"e00180","DOI":"10.1128\/cmr.00180-19","volume":"35","author":"N Dookie","year":"2022","unstructured":"Dookie N, Ngema SL, Perumal R et al (2022) The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives. Clin Microbiol Rev 35:e00180\u2013e00119. https:\/\/doi.org\/10.1128\/cmr.00180-19","journal-title":"Clin Microbiol Rev"},{"key":"4415_CR36","doi-asserted-by":"publisher","first-page":"13259","DOI":"10.3390\/ijms222413259","volume":"22","author":"MA Ejalonibu","year":"2021","unstructured":"Ejalonibu MA, Ogundare SA, Elrashedy AA et al (2021) Drug discovery for Mycobacterium tuberculosis using structure-based computer-aided drug design approach. Int J Mol Sci 22:13259. https:\/\/doi.org\/10.3390\/ijms222413259","journal-title":"Int J Mol Sci"},{"key":"4415_CR37","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1128\/AAC.05690-11","volume":"56","author":"K England","year":"2012","unstructured":"England K, Boshoff HIM, Arora K et al (2012) Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 56:3384. https:\/\/doi.org\/10.1128\/AAC.05690-11","journal-title":"Antimicrob Agents Chemother"},{"key":"4415_CR38","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1586\/eri.12.91","volume":"10","author":"L Favrot","year":"2012","unstructured":"Favrot L, Ronning DR (2012) Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev Anti Infect Ther 10:1023\u20131036. https:\/\/doi.org\/10.1586\/eri.12.91","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4415_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.tube.2015.05.017","volume":"95","author":"N Fogel","year":"2015","unstructured":"Fogel N (2015) Tuberculosis: a disease without boundaries. Tuberculosis 95:527\u2013531. https:\/\/doi.org\/10.1016\/j.tube.2015.05.017","journal-title":"Tuberculosis"},{"key":"4415_CR40","first-page":"569","volume":"6","author":"LM Fu","year":"2002","unstructured":"Fu LM, Fu-Liu CS (2002) Thalidomide and tuberculosis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 6:569\u2013572","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"4415_CR41","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/pharmaceutics13081309","volume":"13","author":"L Garcia-Contreras","year":"2021","unstructured":"Garcia-Contreras L, Sethuraman V, Kazantseva M, Hickey A (2021) Efficacy of combined rifampicin formulations delivered by the pulmonary route to treat tuberculosis in the Guinea pig model. Pharmaceutics 13:1309. https:\/\/doi.org\/10.3390\/pharmaceutics13081309","journal-title":"Pharmaceutics"},{"key":"4415_CR42","doi-asserted-by":"publisher","first-page":"1487518","DOI":"10.3389\/ftubr.2024.1487518","volume":"2","author":"B Gilmour","year":"2024","unstructured":"Gilmour B, Alene KA (2024) Ending tuberculosis: challenges and opportunities. Front Tuberc 2:1487518. https:\/\/doi.org\/10.3389\/ftubr.2024.1487518","journal-title":"Front Tuberc"},{"key":"4415_CR124","unstructured":"Global Tuberculosis Report (2022) Accessed 14 Sept 2024 https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2022"},{"key":"4415_CR44","doi-asserted-by":"publisher","first-page":"106993","DOI":"10.1016\/j.ijid.2024.106993","volume":"141","author":"D Goletti","year":"2024","unstructured":"Goletti D, Al-Abri S, Migliori GB et al (2024) World tuberculosis day 2024 theme yes! We can end TB can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease. Int J Infect Dis 141:106993. https:\/\/doi.org\/10.1016\/j.ijid.2024.106993","journal-title":"Int J Infect Dis"},{"key":"4415_CR45","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41467-019-08405-9","volume":"10","author":"J Gr\u00e4b","year":"2019","unstructured":"Gr\u00e4b J, Su\u00e1rez I, van Gumpel E et al (2019) Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition. Nat Commun 10:688\u2013688. https:\/\/doi.org\/10.1038\/s41467-019-08405-9","journal-title":"Nat Commun"},{"key":"4415_CR46","doi-asserted-by":"publisher","unstructured":"Guglielmetti L, Khan U, Velasquez G et al (2024) Improving treatment of multidrug-resistant tuberculosis: results of the endTB randomised clinical trial. In: Improving treatment of multidrug-resistant tuberculosis: results of the endTB randomised clinical trial. MSF-USA https:\/\/doi.org\/10.57740\/iJRaIStOT9","DOI":"10.57740\/iJRaIStOT9"},{"key":"4415_CR47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12936-024-04967-2","volume":"23","author":"T Hanscheid","year":"2024","unstructured":"Hanscheid T, Del Portal Luyten CR, Hermans SM, Grobusch MP (2024) Repurposing of anti-malarial drugs for the treatment of tuberculosis: realistic strategy or fanciful dead end? Malar J 23:132. https:\/\/doi.org\/10.1186\/s12936-024-04967-2","journal-title":"Malar J"},{"key":"4415_CR48","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.febslet.2006.03.071","volume":"580","author":"N Hasan","year":"2006","unstructured":"Hasan N, Yusuf N, Toossi Z, Islam N (2006) Suppression of Mycobacterium tuberculosis induced reactive oxygen species (ROS) and TNF-\u03b1 mRNA expression in human monocytes by allicin. FEBS Lett 580:2517\u20132522. https:\/\/doi.org\/10.1016\/j.febslet.2006.03.071","journal-title":"FEBS Lett"},{"key":"4415_CR49","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"J Hughes","year":"2011","unstructured":"Hughes J, Rees S, Kalindjian S, Philpott K (2011) Principles of early drug discovery. Br J Pharmacol 162:1239\u20131249. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01127.x","journal-title":"Br J Pharmacol"},{"key":"4415_CR50","doi-asserted-by":"publisher","first-page":"e0181221","DOI":"10.1371\/journal.pone.0181221","volume":"12","author":"J Idh","year":"2017","unstructured":"Idh J, Andersson B, Lerm M et al (2017) Reduced susceptibility of clinical strains of Mycobacterium tuberculosis to reactive nitrogen species promotes survival in activated macrophages. PLoS ONE 12:e0181221. https:\/\/doi.org\/10.1371\/journal.pone.0181221","journal-title":"PLoS ONE"},{"key":"4415_CR51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2015.01.006","volume":"32","author":"K Jabeen","year":"2015","unstructured":"Jabeen K, Shakoor S, Hasan R (2015) Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis 32:118\u2013123. https:\/\/doi.org\/10.1016\/j.ijid.2015.01.006","journal-title":"Int J Infect Dis"},{"key":"4415_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijantimicag.2013.02.019","volume":"42","author":"R-H Jiang","year":"2013","unstructured":"Jiang R-H, Xu H-B, Li L (2013) Comparative roles of Moxifloxacin and Levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents 42:36\u201341. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.02.019","journal-title":"Int J Antimicrob Agents"},{"key":"4415_CR53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/1472-6882-13-258","volume":"13","author":"A Jim\u00e9nez-Arellanes","year":"2013","unstructured":"Jim\u00e9nez-Arellanes A, Luna-Herrera J, Cornejo-Garrido J et al (2013) Ursolic and oleanolic acids as antimicrobial and Immunomodulatory compounds for tuberculosis treatment. BMC Complement Altern Med 13:258. https:\/\/doi.org\/10.1186\/1472-6882-13-258","journal-title":"BMC Complement Altern Med"},{"key":"4415_CR54","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1165\/rcmb.2015-0383OC","volume":"55","author":"E Ju\u00e1rez","year":"2016","unstructured":"Ju\u00e1rez E, Carranza C, S\u00e1nchez G et al (2016) Loperamide restricts intracellular growth of Mycobacterium tuberculosis in lung macrophages. Am J Respir Cell Mol Biol 55:837\u2013847. https:\/\/doi.org\/10.1165\/rcmb.2015-0383OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4415_CR55","doi-asserted-by":"publisher","first-page":"e52706","DOI":"10.7759\/cureus.52706","volume":"16","author":"A Karnan","year":"2024","unstructured":"Karnan A, Jadhav U, Ghewade B et al (2024) A comprehensive review on long vs. short regimens in multidrug-resistant tuberculosis (MDR-TB) under programmatic management of drug-resistant tuberculosis (PMDT). Cureus 16:e52706. https:\/\/doi.org\/10.7759\/cureus.52706","journal-title":"Cureus"},{"key":"4415_CR56","doi-asserted-by":"publisher","first-page":"104289","DOI":"10.1016\/j.phrs.2019.104289","volume":"146","author":"B Khameneh","year":"2019","unstructured":"Khameneh B, Iranshahy M, Vahdati-Mashhadian N et al (2019) Non-antibiotic adjunctive therapy: a promising approach to fight tuberculosis. Pharmacol Res 146:104289. https:\/\/doi.org\/10.1016\/j.phrs.2019.104289","journal-title":"Pharmacol Res"},{"key":"4415_CR57","doi-asserted-by":"publisher","first-page":"106509","DOI":"10.1016\/j.ijantimicag.2021.106509","volume":"59","author":"S Kim","year":"2022","unstructured":"Kim S, Louie A, Drusano GL et al (2022) Evaluating the effect of Clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. Int J Antimicrob Agents 59:106509. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106509","journal-title":"Int J Antimicrob Agents"},{"key":"4415_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00171","author":"A Kolloli","year":"2017","unstructured":"Kolloli A, Subbian S (2017) Host-directed therapeutic strategies for tuberculosis. Front Med. https:\/\/doi.org\/10.3389\/fmed.2017.00171","journal-title":"Front Med"},{"key":"4415_CR83","doi-asserted-by":"publisher","unstructured":"Kumar S, Sharma C, Kaushik SR et al (2019) The phytochemical Bergenin as an adjunct immunotherapy for tuberculosis in mice. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.RA119.008005","DOI":"10.1074\/jbc.RA119.008005"},{"key":"4415_CR60","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.arbres.2023.09.009","volume":"59","author":"S Lac\u00e1mara","year":"2023","unstructured":"Lac\u00e1mara S, Martin C (2023) MTBVAC: a tuberculosis vaccine candidate advancing towards clinical efficacy trials in TB prevention. Arch Bronconeumol 59:821\u2013828. https:\/\/doi.org\/10.1016\/j.arbres.2023.09.009","journal-title":"Arch Bronconeumol"},{"key":"4415_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/infdis\/jiz064","volume":"220","author":"E Lachmandas","year":"2019","unstructured":"Lachmandas E, Eckold C, B\u00f6hme J et al (2019) Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects. J Infect Dis 220:139\u2013150. https:\/\/doi.org\/10.1093\/infdis\/jiz064","journal-title":"J Infect Dis"},{"key":"4415_CR62","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z Lan","year":"2020","unstructured":"Lan Z, Ahmad N, Baghaei P et al (2020) Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 8:383\u2013394. https:\/\/doi.org\/10.1016\/S2213-2600(20)30047-3","journal-title":"Lancet Respir Med"},{"key":"4415_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/09031936.00188313","volume":"44","author":"C Lange","year":"2014","unstructured":"Lange C, Abubakar I, Alffenaar J-WC et al (2014) Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in europe: a TBNET consensus statement. Eur Respir J 44:23\u201363. https:\/\/doi.org\/10.1183\/09031936.00188313","journal-title":"Eur Respir J"},{"key":"4415_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23041964","author":"JV Lara-Espinosa","year":"2022","unstructured":"Lara-Espinosa JV, Arce-Aceves MF, L\u00f3pez-Torres MO et al (2022) Effect of curcumin in experimental pulmonary tuberculosis: antimycobacterial activity in the lungs and anti-inflammatory effect in the brain. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23041964","journal-title":"Int J Mol Sci"},{"key":"4415_CR65","doi-asserted-by":"publisher","first-page":"2386030","DOI":"10.1080\/07853890.2024.2386030","volume":"56","author":"S Leo","year":"2024","unstructured":"Leo S, Narasimhan M, Rathinam S, Banerjee A (2024) Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review. Ann Med 56:2386030. https:\/\/doi.org\/10.1080\/07853890.2024.2386030","journal-title":"Ann Med"},{"key":"4415_CR66","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.2147\/IJN.S257758","volume":"15","author":"Q Liang","year":"2020","unstructured":"Liang Q, Xiang H, Li X et al (2020) Development of rifapentine-loaded PLGA-based nanoparticles: in vitro characterisation and in vivo study in mice. Int J Nanomed 15:7491\u20137507. https:\/\/doi.org\/10.2147\/IJN.S257758","journal-title":"Int J Nanomed"},{"key":"4415_CR67","doi-asserted-by":"publisher","unstructured":"Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase Inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F\u201333F. https:\/\/doi.org\/10.1016\/j.amjcard.2005.06.009","DOI":"10.1016\/j.amjcard.2005.06.009"},{"key":"4415_CR68","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.3390\/cimb46060348","volume":"46","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li H, Dai D et al (2024) Gene regulatory mechanism of Mycobacterium tuberculosis during dormancy. Curr Issues Mol Biol 46:5825\u20135844. https:\/\/doi.org\/10.3390\/cimb46060348","journal-title":"Curr Issues Mol Biol"},{"key":"4415_CR69","doi-asserted-by":"publisher","first-page":"e02510","DOI":"10.1128\/spectrum.02510-23","volume":"12","author":"Y Long","year":"2023","unstructured":"Long Y, Wang B, Xie T et al (2023) Overexpression of efflux pump genes is one of the mechanisms causing drug resistance in Mycobacterium tuberculosis. Microbiol Spectr 12:e02510\u2013e02523. https:\/\/doi.org\/10.1128\/spectrum.02510-23","journal-title":"Microbiol Spectr"},{"key":"4415_CR70","doi-asserted-by":"publisher","first-page":"14348","DOI":"10.3390\/molecules200814348","volume":"20","author":"S L\u00f3pez-Garc\u00eda","year":"2015","unstructured":"L\u00f3pez-Garc\u00eda S, Casta\u00f1eda-Sanchez JI, Jim\u00e9nez-Arellanes A et al (2015) Macrophage activation by ursolic and oleanolic acids during mycobacterial infection. Molecules 20:14348\u201314364. https:\/\/doi.org\/10.3390\/molecules200814348","journal-title":"Molecules"},{"key":"4415_CR71","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/antibiotics13090834","volume":"13","author":"B Lorente-Torres","year":"2024","unstructured":"Lorente-Torres B, Llano-Verdeja J, Casta\u00f1era P et al (2024) Innovative strategies in drug repurposing to tackle intracellular bacterial pathogens. Antibiotics 13:834. https:\/\/doi.org\/10.3390\/antibiotics13090834","journal-title":"Antibiotics"},{"key":"4415_CR72","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/molecules25030665","volume":"25","author":"SJY Macalino","year":"2020","unstructured":"Macalino SJY, Billones JB, Organo VG, Carrillo MCO (2020) In Silico strategies in tuberculosis drug discovery. Mol Basel Switz 25:665. https:\/\/doi.org\/10.3390\/molecules25030665","journal-title":"Mol Basel Switz"},{"key":"4415_CR73","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1038\/s41467-020-19959-4","volume":"11","author":"JS Mackenzie","year":"2020","unstructured":"Mackenzie JS, Lamprecht DA, Asmal R et al (2020) Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis. Nat Commun 11:6092. https:\/\/doi.org\/10.1038\/s41467-020-19959-4","journal-title":"Nat Commun"},{"key":"4415_CR74","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1186\/s13063-022-06772-1","volume":"23","author":"T Maitre","year":"2022","unstructured":"Maitre T, Bonnet M, Calmy A et al (2022) Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial. Trials 23:928. https:\/\/doi.org\/10.1186\/s13063-022-06772-1","journal-title":"Trials"},{"key":"4415_CR75","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani P, Abubakar I, Ariti C et al (2014) Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58:470\u2013480. https:\/\/doi.org\/10.1093\/cid\/cit790","journal-title":"Clin Infect Dis"},{"key":"4415_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1380848","author":"J Mi","year":"2024","unstructured":"Mi J, Wu X, Liang J (2024) The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2024.1380848","journal-title":"Front Microbiol"},{"key":"4415_CR77","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ijid.2020.01.042","volume":"92","author":"GB Migliori","year":"2020","unstructured":"Migliori GB, Tiberi S, Zumla A et al (2020) MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the global tuberculosis network. Int J Infect Dis 92:S15\u2013S25. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.042","journal-title":"Int J Infect Dis"},{"key":"4415_CR78","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1021\/acsanm.9b02089","volume":"3","author":"N Mistry","year":"2020","unstructured":"Mistry N, Bandyopadhyaya R, Mehra S (2020) ZnO nanoparticles and rifampicin synergistically damage the membrane of Mycobacteria. ACS Appl Nano Mater 3:3174\u20133184. https:\/\/doi.org\/10.1021\/acsanm.9b02089","journal-title":"ACS Appl Nano Mater"},{"key":"4415_CR79","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","volume":"22","author":"N Ndjeka","year":"2022","unstructured":"Ndjeka N, Campbell JR, Meintjes G et al (2022) Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South africa: a retrospective cohort study. Lancet Infect Dis 22:1042\u20131051. https:\/\/doi.org\/10.1016\/S1473-3099(21)00811-2","journal-title":"Lancet Infect Dis"},{"key":"4415_CR80","doi-asserted-by":"publisher","first-page":"656419","DOI":"10.3389\/fimmu.2021.656419","volume":"12","author":"M Ozturk","year":"2021","unstructured":"Ozturk M, Chia JE, Hazra R et al (2021) Evaluation of Berberine as an adjunct to TB treatment. Front Immunol 12:656419. https:\/\/doi.org\/10.3389\/fimmu.2021.656419","journal-title":"Front Immunol"},{"key":"4415_CR81","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3389\/fimmu.2019.00894","volume":"10","author":"SA Prabowo","year":"2019","unstructured":"Prabowo SA, Painter H, Zelmer A et al (2019) RUTI vaccination enhances Inhibition of mycobacterial growth ex vivo and induces a shift of monocyte phenotype in mice. Front Immunol 10:894. https:\/\/doi.org\/10.3389\/fimmu.2019.00894","journal-title":"Front Immunol"},{"key":"4415_CR82","doi-asserted-by":"publisher","first-page":"g4643","DOI":"10.1136\/bmj.g4643","volume":"349","author":"A Roy","year":"2014","unstructured":"Roy A, Eisenhut M, Harris RJ et al (2014) Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 349:g4643\u2013g4643. https:\/\/doi.org\/10.1136\/bmj.g4643","journal-title":"BMJ"},{"key":"4415_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.25259\/IJMS_18_2019","volume":"71","author":"S Saha","year":"2020","unstructured":"Saha S, Kumar A, Saurabh K et al (2020) Current status of treatment of latent tuberculosis infection in India. Indian J Med Sci 71:54\u201359. https:\/\/doi.org\/10.25259\/IJMS_18_2019","journal-title":"Indian J Med Sci"},{"key":"4415_CR85","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/nano13020269","volume":"13","author":"S Sangboonruang","year":"2023","unstructured":"Sangboonruang S, Semakul N, Suriyaprom S et al (2023) Nano-delivery system of ethanolic extract of propolis targeting Mycobacterium tuberculosis via aptamer-modified-niosomes. Nanomater Basel Switz 13:269. https:\/\/doi.org\/10.3390\/nano13020269","journal-title":"Nanomater Basel Switz"},{"key":"4415_CR86","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1139\/cjpp-2021-0008","volume":"99","author":"S Sanjay","year":"2021","unstructured":"Sanjay S, Girish C, Toi PC, Bobby Z (2021) Quercetin modulates NRF2 and NF-\u03baB\/TLR-4 pathways to protect against isoniazid- and rifampicin-induced hepatotoxicity in vivo. Can J Physiol Pharmacol 99:952\u2013963. https:\/\/doi.org\/10.1139\/cjpp-2021-0008","journal-title":"Can J Physiol Pharmacol"},{"key":"4415_CR87","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.PA4634","author":"N Sarangdhar","year":"2019","unstructured":"Sarangdhar N, Mohanty KC (2019) Efficacy and safety of levamisole as an Immunomodulator in the treatment of drug resistant tuberculosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.congress-2019.PA4634","journal-title":"Eur Respir J"},{"key":"4415_CR88","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1039\/D2RA08196B","volume":"13","author":"B Sarkar","year":"2023","unstructured":"Sarkar B, Mahapa A, Dey K et al (2023) Aza-Michael promoted glycoconjugation of PETIM dendrimers and selectivity in mycobacterial growth inhibitions. RSC Adv 13:4669\u20134677. https:\/\/doi.org\/10.1039\/D2RA08196B","journal-title":"RSC Adv"},{"key":"4415_CR58","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML (2015) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 5:a017863. https:\/\/doi.org\/10.1101\/cshperspect.a017863","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4415_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5455\/njppp.2024.14.04164202416042024","volume":"14","author":"A Shah","year":"2024","unstructured":"Shah A, Shah S (2024a) Recent advances in drug therapy for tuberculosis. Natl J Physiol Pharm Pharmacol 14:1. https:\/\/doi.org\/10.5455\/njppp.2024.14.04164202416042024","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"4415_CR91","doi-asserted-by":"publisher","first-page":"805","DOI":"10.5455\/njppp.2024.14.04164202416042024","volume":"14","author":"AM Shah","year":"2024","unstructured":"Shah AM, Shah SV (2024b) Recent advances in drug therapy for tuberculosis. Natl J Physiol Pharm Pharmacol 14:805\u2013805. https:\/\/doi.org\/10.5455\/njppp.2024.14.04164202416042024","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"4415_CR92","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1021\/acsomega.2c05511","volume":"8","author":"K Sharma","year":"2023","unstructured":"Sharma K, Ahmed F, Sharma T et al (2023) Potential repurposed drug candidates for tuberculosis treatment: progress and update of drugs identified in over a decade. ACS Omega 8:17362\u201317380. https:\/\/doi.org\/10.1021\/acsomega.2c05511","journal-title":"ACS Omega"},{"key":"4415_CR93","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1038\/s41598-022-13682-4","volume":"12","author":"M Sheikhpour","year":"2022","unstructured":"Sheikhpour M, Delorme V, Kasaeian A et al (2022) An effective nano drug delivery and combination therapy for the treatment of tuberculosis. Sci Rep 12:9591. https:\/\/doi.org\/10.1038\/s41598-022-13682-4","journal-title":"Sci Rep"},{"key":"4415_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151668","author":"JD Simmons","year":"2021","unstructured":"Simmons JD, Hawn TR (2021) Remodeling the matrix: Doxycycline modulates tuberculosis immunopathology. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI151668","journal-title":"J Clin Invest"},{"key":"4415_CR95","doi-asserted-by":"publisher","unstructured":"Singh B, Cocker D, Ryan H, Sloan DJ (2019) Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2019:CD012836. https:\/\/doi.org\/10.1002\/14651858.CD012836.pub2","DOI":"10.1002\/14651858.CD012836.pub2"},{"key":"4415_CR96","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.csbj.2021.04.034","volume":"19","author":"P Singh","year":"2021","unstructured":"Singh P, Jamal S, Ahmed F et al (2021) Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis. Comput Struct Biotechnol J 19:2423\u20132446. https:\/\/doi.org\/10.1016\/j.csbj.2021.04.034","journal-title":"Comput Struct Biotechnol J"},{"key":"4415_CR97","doi-asserted-by":"publisher","first-page":"106968","DOI":"10.1016\/j.ijantimicag.2023.106968","volume":"62","author":"S Singh","year":"2023","unstructured":"Singh S, Gumbo T, Alffenaar J-W et al (2023) Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. Int J Antimicrob Agents 62:106968. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106968","journal-title":"Int J Antimicrob Agents"},{"key":"4415_CR98","doi-asserted-by":"publisher","first-page":"e0263304","DOI":"10.1371\/journal.pone.0263304","volume":"17","author":"AY Soeroto","year":"2022","unstructured":"Soeroto AY, Nurhayati RD, Purwiga A et al (2022) Factors associated with treatment outcome of MDR\/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. PLoS ONE 17:e0263304. https:\/\/doi.org\/10.1371\/journal.pone.0263304","journal-title":"PLoS ONE"},{"key":"4415_CR99","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","volume":"14","author":"JAM Stadler","year":"2023","unstructured":"Stadler JAM, Maartens G, Meintjes G, Wasserman S (2023) Clofazimine for the treatment of tuberculosis. Front Pharmacol 14:1100488. https:\/\/doi.org\/10.3389\/fphar.2023.1100488","journal-title":"Front Pharmacol"},{"key":"4415_CR100","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/pharmaceutics13050592","volume":"13","author":"F Stephanie","year":"2021","unstructured":"Stephanie F, Saragih M, Tambunan USF (2021) Recent progress and challenges for drug-resistant tuberculosis treatment. Pharmaceutics 13:592. https:\/\/doi.org\/10.3390\/pharmaceutics13050592","journal-title":"Pharmaceutics"},{"key":"4415_CR101","doi-asserted-by":"publisher","unstructured":"Stephens F, Gandhi NR, Brust JCM et al (2019) Treatment adherence among persons receiving concurrent multidrug-resistant tuberculosis and human immunodeficiency virus treatment in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 82:124\u2013130. https:\/\/doi.org\/10.1097\/QAI.0000000000002120","DOI":"10.1097\/QAI.0000000000002120"},{"key":"4415_CR102","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1128\/AAC.01446-06","volume":"51","author":"DR Stickney","year":"2007","unstructured":"Stickney DR, Noveljic Z, Garsd A et al (2007) Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. Antimicrob Agents Chemother 51:2639\u20132641. https:\/\/doi.org\/10.1128\/AAC.01446-06","journal-title":"Antimicrob Agents Chemother"},{"key":"4415_CR103","doi-asserted-by":"publisher","first-page":"e03208","DOI":"10.1128\/mbio.03208-23","volume":"15","author":"A Sturm","year":"2024","unstructured":"Sturm A, Sun P, Avila-Pacheco J et al (2024) Genetic factors affecting storage and utilization of lipids during dormancy in Mycobacterium tuberculosis. mBio 15:e03208\u2013e03223. https:\/\/doi.org\/10.1128\/mbio.03208-23","journal-title":"mBio"},{"key":"4415_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00238","author":"S Subbian","year":"2016","unstructured":"Subbian S, Koo M-S, Tsenova L et al (2016) Pharmacologic Inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2016.00238","journal-title":"Front Immunol"},{"key":"4415_CR105","doi-asserted-by":"publisher","unstructured":"Szumowski JD, Adams KN, Edelstein PH, Ramakrishnan L (2013) Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr Top Microbiol Immunol 374. https:\/\/doi.org\/10.1007\/82_2012_300. 10.1007\/82_2012_300","DOI":"10.1007\/82_2012_300"},{"key":"4415_CR106","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.ssmqr.2022.100042","volume":"2","author":"HA Taylor","year":"2022","unstructured":"Taylor HA, Dowdy DW, Searle AR et al (2022) Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB). SSM Qual Res Health 2:100042. https:\/\/doi.org\/10.1016\/j.ssmqr.2022.100042","journal-title":"SSM Qual Res Health"},{"key":"4415_CR107","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","volume":"124","author":"S Tiberi","year":"2022","unstructured":"Tiberi S, Utjesanovic N, Galvin J et al (2022) Drug resistant TB\u2014latest developments in epidemiology, diagnostics and management. Int J Infect Dis 124:S20\u2013S25. https:\/\/doi.org\/10.1016\/j.ijid.2022.03.026","journal-title":"Int J Infect Dis"},{"key":"4415_CR108","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijtb.2020.07.017","volume":"67","author":"T Umumararungu","year":"2020","unstructured":"Umumararungu T, Mukazayire MJ, Mpenda M et al (2020) A review of recent advances in anti-tubercular drug development. Indian J Tuberc 67:539\u2013559. https:\/\/doi.org\/10.1016\/j.ijtb.2020.07.017","journal-title":"Indian J Tuberc"},{"key":"4415_CR109","doi-asserted-by":"publisher","first-page":"107741","DOI":"10.1016\/j.ijid.2024.107741","volume":"152","author":"PA Van Rie","year":"2025","unstructured":"Van Rie PA, Van Rie PA, Warren PR et al (2025) The role of AI in combatting RR-TB epidemics. Int J Infect Dis 152:107741. https:\/\/doi.org\/10.1016\/j.ijid.2024.107741","journal-title":"Int J Infect Dis"},{"key":"4415_CR110","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.2217\/nnm-2017-0248","volume":"12","author":"AC Vieira","year":"2017","unstructured":"Vieira AC, Magalh\u00e3es J, Rocha S et al (2017) Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment. Nanomedicine 12:2721\u20132736. https:\/\/doi.org\/10.2217\/nnm-2017-0248","journal-title":"Nanomedicine"},{"key":"4415_CR111","doi-asserted-by":"crossref","unstructured":"Vijayan V, De S (2009) In: Tuberculosis (ed) Pulmonary tuberculosis. Jaypee Brothers Medical Publishers (P) Ltd., pp 217\u2013217","DOI":"10.5005\/jp\/books\/10992_14"},{"key":"4415_CR112","doi-asserted-by":"publisher","first-page":"e50222","DOI":"10.7759\/cureus.50222","volume":"15","author":"D Vishwakarma","year":"2023","unstructured":"Vishwakarma D, Gaidhane A, Sahu S, Rathod AS (2023) Multi-drug resistance tuberculosis (MDR-TB) challenges in india: a review. Cureus 15:e50222. https:\/\/doi.org\/10.7759\/cureus.50222","journal-title":"Cureus"},{"key":"4415_CR113","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/vaccines8040586","volume":"8","author":"E Whitlow","year":"2020","unstructured":"Whitlow E, Mustafa AS, Hanif SNM (2020) An overview of the development of new vaccines for tuberculosis. Vaccines 8:586. https:\/\/doi.org\/10.3390\/vaccines8040586","journal-title":"Vaccines"},{"key":"4415_CR115","unstructured":"World Health Organization (2025) WHO consolidated guidelines on tuberculosis: module 4: treatment and care. In: WHO consolidated guidelines on tuberculosis: module 4: treatment and care https:\/\/www.who.int\/publications\/i\/item\/9789240107243"},{"key":"4415_CR114","volume-title":"WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents","author":"World Health Organization","year":"2022","unstructured":"World Health Organization (2022) WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. World Health Organization, Geneva"},{"key":"4415_CR116","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) Global tuberculosis report 2024, 1st edn. World Health Organization, Geneva","edition":"1"},{"key":"4415_CR117","doi-asserted-by":"publisher","first-page":"123118","DOI":"10.1016\/j.jchromb.2022.123118","volume":"1191","author":"W Wu","year":"2022","unstructured":"Wu W, Li K, Zhao C et al (2022) A rapid HPLC\u2013MS\/MS method for the simultaneous determination of luteolin, Resveratrol and their metabolites in rat plasma and its application to Pharmacokinetic interaction studies. J Chromatogr B 1191:123118. https:\/\/doi.org\/10.1016\/j.jchromb.2022.123118","journal-title":"J Chromatogr B"},{"key":"4415_CR119","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41479-024-00133-z","volume":"16","author":"J Yayan","year":"2024","unstructured":"Yayan J, Franke K-J, Berger M et al (2024) Early detection of tuberculosis: a systematic review. Pneumonia 16:11. https:\/\/doi.org\/10.1186\/s41479-024-00133-z","journal-title":"Pneumonia"},{"key":"4415_CR120","doi-asserted-by":"publisher","unstructured":"Zheng H, Abramovitch RB (2019) Inhibiting DosRST as a new approach to tuberculosis therapy. Future Med Chem 12:457\u2013467. https:\/\/doi.org\/10.4155\/fmc-2019-0263","DOI":"10.4155\/fmc-2019-0263"},{"key":"4415_CR121","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3390\/microorganisms11102469","volume":"11","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Wattiez R, Constant P et al (2023) Telacebec interferes with virulence lipid biosynthesis protein expression and sensitizes to other antibiotics. Microorganisms 11:2469. https:\/\/doi.org\/10.3390\/microorganisms11102469","journal-title":"Microorganisms"},{"key":"4415_CR122","doi-asserted-by":"publisher","first-page":"30904","DOI":"10.1021\/acsomega.4c03795","volume":"9","author":"J Zhu","year":"2024","unstructured":"Zhu J, Cheng W, He T-T et al (2024) Exploring the anti-inflammatory effect of tryptanthrin by regulating TLR4\/MyD88\/ROS\/NF-\u03baB, JAK\/STAT3, and Keap1\/Nrf2 signaling pathways. ACS Omega 9:30904\u201330918. https:\/\/doi.org\/10.1021\/acsomega.4c03795","journal-title":"ACS Omega"},{"key":"4415_CR123","doi-asserted-by":"publisher","unstructured":"Ziganshina LE, Titarenko AF, Davies GR (2013) Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 2013:CD004795. https:\/\/doi.org\/10.1002\/14651858.CD004795.pub4","DOI":"10.1002\/14651858.CD004795.pub4"},{"key":"4415_CR126","unstructured":"Henry M. Jackson Foundation for the Advancement of Military Medicine (2020) A Proof-of Concept, Randomized, Controlled Study of Tuberculosis Immunization With BCG to Prevent Infection in Healthy Adults (TIPI Trial) https:\/\/clinicaltrials.gov\/study\/NCT04453293"},{"key":"4415_CR127","unstructured":"A Proof-of Concept, Randomized, Controlled Study of Tuberculosis Immunization With BCG to Prevent Infection in Healthy Adults (TIPI Trial). (2025, 2025-05-22). Retrieved July 1 from. https:\/\/clinicaltrials.gov\/study\/NCT04453293"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-025-04415-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:05:51Z","timestamp":1758719151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-025-04415-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":124,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4415"],"URL":"https:\/\/doi.org\/10.1007\/s00203-025-04415-y","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}